SOPH (Sophia Genetics) 3-Year RORE % : 1.82% (As of Mar. 2026)


SOPH Sophia Genetics SA SOPH
74 GF Score
Price $5.65
GF Value $5.06
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics 3-Year RORE %?

Sophia Genetics SOPH -2.92% 74 3-Year RORE % is 1.82 as of Mar. 2026. GuruFocus rates SOPH with a GF Score™ of 74/100 and a GF Value™ of $5.06 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Sophia Genetics ranks better than 51.32% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Sophia Genetics's 3-Year RORE % for the quarter that ended in Mar. 2026 was 1.82%.

The industry rank for Sophia Genetics's 3-Year RORE % or its related term are showing as below:

SOPH's 3-Year RORE % is ranked better than
51.32% of 606 companies
in the Healthcare Providers & Services industry
Industry Median: 0.195 vs SOPH: 1.82

Sophia Genetics  (NAS:SOPH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Sophia Genetics 3-Year RORE % Related Terms


Sophia Genetics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics 3-Year RORE % Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial 0.00 14.39 -0.37 -11.86 -1.50

Sophia Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.24 -3.59 1.52 -1.50 1.82

SOPH vs WEAV, NRC, MDRX: 3-Year RORE % Comparison

For the Health Information Services subindustry, Sophia Genetics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophia Genetics 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Sophia Genetics's 3-Year RORE % falls into.


SOPH
74GF Score
Sophia Genetics SA SOPH
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sophia Genetics 3-Year RORE % Calculation

Sophia Genetics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.18--1.12 )/( -3.3-0 )
=-0.06/-3.3
=1.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 1.82 mean?
Sophia Genetics (SOPH) has a 3-Year RORE % of 1.82 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #295 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 48.7%.
Is Sophia Genetics' 3-Year RORE % too high?
Sophia Genetics' current 3-Year RORE % is 1.82. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. Sophia Genetics' value of 1.82 is 833.3% above this industry median. Based on the distribution chart, Sophia Genetics ranks #295 out of 606 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' 3-Year RORE % compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #295 out of 606 companies for 3-Year RORE %. This puts Sophia Genetics in the upper half of its industry. The industry median 3-Year RORE % is 0.20. Sophia Genetics' value of 1.82 is 833.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current 3-Year RORE % of 1.82 is 833.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current 3-Year RORE % is 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.06, compared to a current price of $5.65 — trading 11.7% above its estimated fair value. The current 3-Year RORE % is 1.82 and 833.3% above the Healthcare Providers & Services industry median of 0.20. Sophia Genetics' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current 3-Year RORE % is 1.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (SOPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of $5.65 is trading 11.7% above its estimated GF Value™ of $5.06. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for SOPH:

  • 3-Year RORE %: 1.82
  • GF Value™: $5.06 vs. price of $5.65 (11.7% above fair value)
  • GF Score™: 74/100 with 6 warning signs
  • Industry Position: 833.3% above the Healthcare Providers & Services median (#295 of 606)

No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sophia Genetics Business Description

Other Exchanges 90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
74GF Score

Get the complete analysis for SOPH

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.65
Price
$5.06
GF Value